Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05303285 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study Evaluating the Efficacy of Secukinumab 300mg in Chinese Adults With Active Ankylosing Spondylitis

StatusRecruiting
PhasePhase 4
Started2024-06-14
View on ClinicalTrials.gov ↗
Record status
This record was last updated January 27, 2026 (before its estimated August 31, 2026 completion). Its status may not reflect the trial's current state.

Amendment history

2026-01-25
Study Status, Sponsor/Collaborators v1
Primary completion date2022-08-31→2026-08-31
Completion date2022-08-31→2026-08-31
Start date2021-06-14→2024-06-14
Collaborators2 to 4 entries
Novartis Johns Hopkins Bloomberg School of Public Health
2022-03-20
Original filing
The purpose of this study is to evaluate the safety and efficacy of secukinumab 300mg in Chinese adults participants with active ankylosing spondylitis (AS) who have had an inadequate response to at least 2 non-steroidal anti-inflammatory drugs (NSAIDs) or intolerance to or a contraindication for NSAIDs, and who are naïve to biologic disease-modifying anti-rheumatic drugs (bDMARD).
Trial Details
NCT Number NCT05303285
Lead Sponsor Tongji Hospital
Collaborators: Wuhan Central Hospital, Wuhan Hospital of Traditional Chinese Medicine, Novartis, Johns Hopkins Bloomberg School of Public Health
Conditions Ankylosing Spondylitis (AS)
Enrollment 100 participants
Start Date 2024-06-14
Primary Completion 2026-08-31 (estimated)
Study Completion 2026-08-31 (estimated)
Updated on ClinicalTrials.gov 2026-01-27